Home › NDC Lookup › Ingredients › Dimenhydrinate › 00904-2051-12
Driminate Dimenhydrinate 50 mg Tablet, 12-count — NDC 00904-2051-12 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Driminate Dimenhydrinate 50 mg Tablet, 12-count — NDC 0904-2051-12 (Billing 00904-2051-12)

by Major Pharmaceuticals · 2 BLISTER PACK in 1 CARTON / 6 TABLET in 1 BLISTER PACK

This is a package of 12 tablets of Driminate Dimenhydrinate 50 mg Tablet from Major Pharmaceuticals, marketed since Dec 1992 and currently FDA-listed; retail pharmacies pay about $0.0575 per tablet (NADAC).

NDC 00904-2051-12
🏷️ FDA NDC (as labeled) 0904-2051-12 billing pads the labeler segment with a zero
This package
Contains12-count Cost per ea$0.0575 NADAC Per package$0.69 / 12 tablets Pack sizes2 compare ↓
Product page 00904-2051-59 Also comes in: 100 tablets 0904-2051-59
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0904-2051-12 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0904 labeler · 2051 product · 12 package
Package marketed since
Dec 1, 1992
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
12 EA per package
Barcode (UPC)
0309042051590
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0904-2051-12
Product NDC 0904-2051
11-digit billing NDC 00904205112
NCPDP billing unit EA — each (per item)
RxCUI 198603, 211482
UNII JB937PER5C
UPC 0309042051590
Application # M009
SPL Set ID d2967f78-41ee-4c30-8b47-0757df9f3d91
Established class (EPC) Histamine-1 Receptor Antagonist
Mechanism of action Histamine H1 Receptor Antagonists
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1992-12-01
Route ORAL
Dosage form TABLET
Substance DIMENHYDRINATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 50200030000310
GPI class Driminate
GCN Seq No 004720
GCN 18231
HICL code 004603
Ingredient (HICL) Dimenhydrinate
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6J
Therapeutic class — specific (HIC3) Antiemetic/Antivertigo Agents
AHFS code 04:04.00.00
AHFS class First Generation Antihistamines
FDB label name DRIMINATE 50 MG TABLET
FDB brand name Driminate
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 004720
  • GCN: 18231
  • GPI-14 (Medi-Span): 50200030000310
  • HICL (First Databank): 004603
  • AHFS class code: 04:04.00.00
  • RxCUI (RxNorm): 198603
Why two NDCs? The FDA registers this code as 0904-2051-12 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00904-2051-12. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Aminoalkyl ethers class.

Drug family (ATC) Aminoalkyl ethers
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name DRIMINATE 50 MG TABLET Ingredient Dimenhydrinate
📖 What it is MedlinePlus · NLM

Dimenhydrinate is used to prevent and treatmotion sickness. Dimenhydrinate is in a class of medications called antihistamines. It works by preventing problems with body balance.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It prevents and treats the nausea, vomiting and dizziness of motion sickness. You'll see it in products like Dramamine and Gravol, and as an injection used in medical settings.
  • To prevent motion sickness, take your first dose about 30 to 60 minutes before you start traveling. After that, follow the repeat timing and daily limit on your product's label. Ch...
  • Quite possibly. Drowsiness is the most common side effect. Be careful driving or using machinery, and skip alcohol.
  • Tell me what else you take. Sedatives, tranquilizers and other sedating drugs can add to drowsiness. It can also hide warning signs of ear damage from certain antibiotics.
📖 Read our full Dimenhydrinate guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.058 $0.69 / 12 tablets
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Aug 2026 Sep 2026 $0.058 $0.054
▲ Up 6% over the last 2 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00904-2051-59 0904-2051-59 Main listing 1 BOTTLE, PLASTIC in 1 CARTON / 100 TABLET in 1 BOTTLE, PLASTIC $0.0575 / ea $5.75 1992-12-01 — Active
00904-2051-12 You're viewing this 2 BLISTER PACK in 1 CARTON / 6 TABLET in 1 BLISTER PACK $0.0575 / ea $0.69 1992-12-01 — Active

This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.0575 NADAC).

This pack shows little to no recent Medicaid volume — a different pack size carries most fills. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 12-count package — 2 blister pack in 1 carton / 6 tablet in 1 blister pack.
How does this package differ from NDC 00904-2051-59?
Both are Driminate Dimenhydrinate 50 mg Tablet — the drug itself is identical. This page's package is the 12-count one, while NDC 00904-2051-59 is the 100 tablets package.
What NDC number is used to bill for this package of Driminate Dimenhydrinate 50 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Dimenhydrinate 50 mg 70000-0404-01 LEADER/ 12 tablets $0.054 — Availability likely save 6%
Driminate 50 mgthis 00904-2051-12 Major 12 tablets $0.058 — Availability likely —
Dimenhydrinate 50 mg 00904-6772-12 Major 12 tablets $0.058 — Availability likely —
Motion Sickness Relief 50 mg 46122-0536-53 Amerisource 12 tablets $0.058 — Availability likely —
Motion Sickness Relief 50 mg 70000-0749-01 Cardinal 12 tablets $0.058 — Availability likely —
Motion Sickness 50 mg 70677-1087-01 Strategic 12 tablets $0.058 — Availability likely —
Motion Sickness Relief 50 mg 83324-0032-12 Chain 12 tablets $0.058 — Availability likely —
Motion Sickness Relief 50 mg 00363-1980-08 Walgreen 24 tablets — — FDA listed —
Gravol 50 mg 10237-0941-10 Church 10 tablets — — FDA listed —
Motion Sickness 50 mg 11673-0198-02 Target 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 11673-0354-24 TARGET 24 tablets — — FDA listed —
Motion Sickness Relief 50 mg 11822-0198-02 Rite 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 36800-0930-12 Topco 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 49035-0981-12 Wal-Mart 100 tablets — — FDA listed —
Motion Sickness 50 mg 50804-0198-02 Geiss, 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 50844-0199-02 L.N.K. 12 tablets — — FDA listed —
Motion Sickness 50 mg 59779-0198-02 CVS 12 tablets — — FDA listed —
Dramamine Original Formula 50 mg 63029-0901-01 Medtech 36 tablets — — FDA listed —
Motion Sickness Relief 50 mg 63941-0198-02 Valu 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 67091-0118-12 WinCo 12 tablets — — FDA listed —
Motion Sickness Relief 50 mg 69168-0408-86 Allegiant 12 tablets — — FDA listed —
Dimenhydrinate 50 mg 69842-0206-12 CVS 12 tablets — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1992
On the market since
Dec 1992
📍
2026
Currently FDA-listed
34 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeRound
Imprint44;198
Size9 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Dimenhydrinate inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII M28OL1HH48
    Croscarmellose sodium is a plant-based substance derived from cellulose. It acts as a disintegrant, helping tablets and capsules break down quickly in the digestive system so the medicine can be absorbed.
  • UNII O7TSZ97GEP
    A mineral compound that serves as a filler and binding agent in tablets and capsules. It adds bulk to the medicine and helps hold ingredients together during manufacturing.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 4ELV7Z65AP
    Stearic acid is a fatty acid derived from plant or animal sources. It acts as a binder and lubricant in tablets and capsules, helping them hold together and flow smoothly during manufacturing.

6 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statescroscarmellose sodium, dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, stearic acid 

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerMajor Pharmaceuticals
FDA applicationM009 (OTC MONOGRAPH DRUG)
Labeler code00904
First marketedDec 1992
Product typeHuman Otc Drug
Portfolio630 products on file

More NDCs from Major Pharmaceuticals labeler code 00904

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 📦 Storage and Handling 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Do Not Use 📄 Ask a Doctor Before Use If 📄 Ask a Doctor or Pharmacist Before Use If 📄 When Using This Product 🤰 If Pregnant or Breast-Feeding 📄 Keep Out of Reach of Children 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 15 words ▾

Uses for prevention and treatment of these symptoms associated with motion sickness: nausea vomiting dizziness

⏱️ Dosage and Administration 128 words ▾

Directions do not take more than directed to prevent motion sickness, the first dose should be taken 1/2 to 1 hour before starting activity to prevent or treat motion sickness, see below: adults and children 12 years and over ■ take 1 to 2 tablets every 4-6 hours ■ do not take more than 8 tablets in 24 hours, or as directed by a doctor children 6 to under 12 years ■ give 1/2 to 1 tablet every 6-8 hours ■ do not give more than 3 tablets in 24 hours, or as directed by a doctor children 2 to under 6 years ■ give 1/2 tablet every 6-8 hours ■ do not give more than 1 1/2 tablets in 24 hours, or as directed by a doctor

⚠️ Warnings 117 words ▾

Warnings Do not use for children under 2 years of age unless directed by a doctor. Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers. When using this product alcohol, sedatives, and tranquilizers may increase drowsiness marked drowsiness may occur use caution when driving a motor vehicle or operating machinery avoid alcoholic beverages If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

📦 Storage and Handling 29 words ▾

Other information each tablet contains: calcium 35 mg protect from moisture store at 25ºC (77ºF); excursions permitted between 15º-30ºC (59º-86ºF) see end flap for expiration date and lot number

🧪 Active Ingredient 8 words ▾

Active ingredient (in each tablet) Dimenhydrinate 50 mg

🧪 Inactive Ingredients 16 words ▾

Inactive ingredients croscarmellose sodium, dibasic calcium phosphate dihydrate, magnesium stearate, microcrystalline cellulose, silicon dioxide, stearic acid

🎯 Purpose 2 words ▾

Purpose Antiemetic

📄 Do Not Use 15 words ▾

Do not use for children under 2 years of age unless directed by a doctor.

📄 Ask a Doctor Before Use If 28 words ▾

Ask a doctor before use if you have a breathing problem such as emphysema or chronic bronchitis glaucoma difficulty in urination due to enlargement of the prostate gland

📄 Ask a Doctor or Pharmacist Before Use If 14 words ▾

Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers.

📄 When Using This Product 28 words ▾

When using this product alcohol, sedatives, and tranquilizers may increase drowsiness marked drowsiness may occur use caution when driving a motor vehicle or operating machinery avoid alcoholic beverages

🤰 If Pregnant or Breast-Feeding 10 words ▾

If pregnant or breast-feeding, ask a health professional before use.

📄 Keep Out of Reach of Children 21 words ▾

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

📄 Questions or Comments 4 words ▾

Questions or comments? 1-800-426-9391

📄 Package Label / Principal Display Panel 97 words ▾

Principal Display Panel MAJOR ® NDC 0904-2051-59 compare to the active ingredient in Dramamine ® Original Formula* Driminate™ dimenhydrinate 50 mg antiemetic for nausea, dizziness and vomiting from motion sickness 100 tablets dye-free actual size TAMPER EVIDENT: DO NOT USE IF IMPRINTED SAFETY SEAL UNDER CAP IS BROKEN OR MISSING Rev. 04/26 M-17 Re-order No. 700621 *This product is not manufactured or distributed by Medtech Products Inc., owner of the registered trademark Dramamine ® Original Formula.

50844 REV0226Q19812 Distributed by: MAJOR ® PHARMACEUTICALS Indianapolis, IN 46268 (800) 616-2471 www.major-rugby.com Major 44 -198 REV0226Q Major 44 -198 REV0226Q

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets00904-2051-59 663 Rx · $5,657
12 tablets this page00904-2051-12 No Medicaid data
Drug total (last 4 qtrs): 663 Rx · 25,409 units · $5,657 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)

Medicare Part D (outpatient prescription) spending for Dimenhydrinate (matched by generic name) — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Dimenhydrinate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Total Part D spend
$4K
Claims incl. refills
15
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$269.22
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Driminate (this brand).

Top reported reactions

Febrile Neutropenia811
Nausea671
Vomiting448
Fatigue423
Pyrexia416
Condition Aggravated355
Dyspnoea323

Age at onset

Neonate35
Infant56
Child194
Adolescent97
Adult671
Elderly318

Reporter sex

5,242 reports
Male · 42%
Female · 58%
Unknown · 0%

Serious outcomes

Hospitalization3,008
Life-threatening852
Death520
Disabling188
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 628 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 00904-2015-59 · Major 00904-2056-61 · Major →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.